APA

Fensome A., Ambler C. M., Arnold E., Banker M. E., Brown M. F., Chrencik J., Clark J. D., Dowty M. E., Efremov I. V., Flick A., Gerstenberger B. S., Gopalsamy A., Hayward M. M., Hegen M., Hollingshead B. D., Jussif J., Knafels J. D., Limburg D. C., Lin D., Lin T. H., Pierce B. S., Saiah E., Sharma R., Symanowicz P. T., Telliez J., Trujillo J. I., Vajdos F. F., Vincent F., Wan Z., Xing L., Yang X., Yang X. & Zhang L. (20191007). Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of (( S)-2,2-Difluorocyclopropyl)((1 R,5 S)-3-(2-((1-methyl-1 H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841). : Journal of medicinal chemistry.

Chicago

Fensome Andrew, Ambler Catherine M, Arnold Eric, Banker Mary Ellen, Brown Matthew F, Chrencik Jill, Clark James D, Dowty Martin E, Efremov Ivan V, Flick Andrew, Gerstenberger Brian S, Gopalsamy Ariamala, Hayward Matthew M, Hegen Martin, Hollingshead Brett D, Jussif Jason, Knafels John D, Limburg David C, Lin David, Lin Tsung H, Pierce Betsy S, Saiah Eddine, Sharma Raman, Symanowicz Peter T, Telliez Jean-Baptiste, Trujillo John I, Vajdos Felix F, Vincent Fabien, Wan Zhao-Kui, Xing Li, Yang Xiaojing, Yang Xin and Zhang Liying. 20191007. Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of (( S)-2,2-Difluorocyclopropyl)((1 R,5 S)-3-(2-((1-methyl-1 H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841). : Journal of medicinal chemistry.

Harvard

Fensome A., Ambler C. M., Arnold E., Banker M. E., Brown M. F., Chrencik J., Clark J. D., Dowty M. E., Efremov I. V., Flick A., Gerstenberger B. S., Gopalsamy A., Hayward M. M., Hegen M., Hollingshead B. D., Jussif J., Knafels J. D., Limburg D. C., Lin D., Lin T. H., Pierce B. S., Saiah E., Sharma R., Symanowicz P. T., Telliez J., Trujillo J. I., Vajdos F. F., Vincent F., Wan Z., Xing L., Yang X., Yang X. and Zhang L. (20191007). Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of (( S)-2,2-Difluorocyclopropyl)((1 R,5 S)-3-(2-((1-methyl-1 H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841). : Journal of medicinal chemistry.

MLA

Fensome Andrew, Ambler Catherine M, Arnold Eric, Banker Mary Ellen, Brown Matthew F, Chrencik Jill, Clark James D, Dowty Martin E, Efremov Ivan V, Flick Andrew, Gerstenberger Brian S, Gopalsamy Ariamala, Hayward Matthew M, Hegen Martin, Hollingshead Brett D, Jussif Jason, Knafels John D, Limburg David C, Lin David, Lin Tsung H, Pierce Betsy S, Saiah Eddine, Sharma Raman, Symanowicz Peter T, Telliez Jean-Baptiste, Trujillo John I, Vajdos Felix F, Vincent Fabien, Wan Zhao-Kui, Xing Li, Yang Xiaojing, Yang Xin and Zhang Liying. Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of (( S)-2,2-Difluorocyclopropyl)((1 R,5 S)-3-(2-((1-methyl-1 H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841). : Journal of medicinal chemistry. 20191007.